M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 37 of 54
Bioprosthetic Mesh to Expand the Lower Pole in Tissue Expander Reconstruction
NCT01310075
Nuclear and Near-Infrared (NIR) Imaging in Melanoma
NCT01295931
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
NCT01059305
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
NCT01169636
Prevention of Treatment Induced Neuropathy in Multiple Myeloma
NCT01283997
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
NCT01254890
Reducing Tobacco Related Health Disparities
NCT00984724
The Role of the EKG in Anticancer Drug Development
NCT01462383
Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer
NCT01259284
Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas
NCT01276613
Single Session Spine Stereotactic Radiosurgery in Metastatic Epidural Spinal Cord Compression
NCT01256554
Delayed-Delayed Breast Reconstruction
NCT01256528
Phase l/II Study of Ruxolitinib for Acute Leukemia
NCT01251965
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
NCT01200342
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
NCT01237951
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
NCT01168921
CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
NCT01202409
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
NCT01036087
Study of SB939 in Subjects With Myelofibrosis
NCT01200498
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
NCT00943943
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
NCT01198067
Trimodality Management of T1b Esophageal Cancers
NCT01217060
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
NCT01213238
Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer
NCT01205672
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
NCT01197170
Neoadjuvant Ipilimumab in Prostate Cancer
NCT01194271
Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia
NCT01204788
Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma
NCT01176604
Temsirolimus In Phase 0
NCT01417065
Azacitidine and CAPOX in Metastatic Colorectal Cancer
NCT01193517
4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies
NCT01139151
Multimedia Patient Education
NCT01184534
Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol
NCT01196130
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
NCT01183663
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
NCT01185366
Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
NCT01160354
Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems
NCT01193036
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
NCT01191749
Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.
NCT01173692
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
NCT01174082
Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies
NCT01165658
Trientine and Carboplatin in Advanced Malignancies
NCT01178112
Survivorship in Lynch Syndrome Families
NCT01126840
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
NCT01094860
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
NCT01134575
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib
NCT01143779
Bendamustine and Bevacizumab for Advanced Cancers
NCT01152203
Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients
NCT01157533
Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)
NCT01134146
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
NCT00960752
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.